$500m-Plus Pours Into China Bioventures In A Week
$3bn JD Health IPO Planned
Executive Summary
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
You may also be interested in...
China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Need a specific report? 1000+ reports available
Buy Reports